Healthcare AI is entering a critical transition phase where the real work begins not in research labs, but in hospitals and clinics treating actual patients. Rather than celebrating breakthrough algorithms, health systems are now grappling with the harder challenge of turning experimental AI tools into reliable, trustworthy systems that clinicians can depend on every day. This shift from experimentation to implementation at scale emerged as a central theme at PlatforMed 2026, Mayo Clinic's annual innovation conference, where over 260 health system executives gathered to discuss how to make AI work in real-world clinical settings.

What Does It Actually Take to Deploy AI in Hospitals?

Mayo Clinic currently has hundreds of clinical AI solutions in development, ranging from tools that organize complex medical records to systems designed to help radiologists spot diseases earlier. One example highlighted at the conference involves a Mayo Clinic radiologist using AI to detect pancreatic cancer that cannot yet be seen by the human eye, potentially identifying signs of disease well before conventional diagnosis would catch it. However, getting these tools from the research phase into clinical practice requires far more than just having a working algorithm.

"Healthcare is entering a new phase in the adoption of AI. Our responsibility is to ensure these technologies translate into better care for patients. With trusted data and strong governance, AI can help healthcare professionals make more informed decisions in real time, accelerate discovery and improve outcomes," said Dr. John Halamka, the Dwight and Dian Diercks President of Mayo Clinic Platform.

Dr. John Halamka, President of Mayo Clinic Platform

The infrastructure required to support AI at scale involves three interconnected elements. First, health systems must build trusted data infrastructure that ensures patient information is accurate, secure, and properly governed. Second, they need to support their clinical workforce by training doctors, nurses, and other staff to work effectively alongside AI tools. Third, organizations must establish clear processes for turning collaboration and innovation into measurable improvements in actual patient outcomes, not just laboratory metrics.

How Are Fertility Specialists Integrating AI Into Patient Care?

Beyond general clinical settings, specialized medical fields are also navigating the AI implementation challenge. The American Society for Reproductive Medicine (ASRM) recently published a critical guide examining how artificial intelligence and machine learning are being deployed in in vitro fertilization (IVF) laboratories. This represents a particularly nuanced application of AI, since fertility treatment involves not just diagnosis but also personalized treatment protocols, genomic analysis, and outcome prediction for individual patients.

The ASRM's analysis reflects a broader healthcare trend: as AI tools become more sophisticated, medical professionals need clearer frameworks for understanding what these systems can and cannot do reliably. In the IVF context, this means evaluating machine learning systems that assist embryologists in selecting viable embryos, predicting treatment success rates, and tailoring protocols to individual patient characteristics. The stakes are high because these decisions directly affect whether patients achieve pregnancy and have healthy children.

What Regulatory Guardrails Are Shaping AI Deployment?

As AI tools proliferate across healthcare, regulators are working to establish appropriate oversight without stifling innovation. The U.S. Food and Drug Administration (FDA) recently updated its guidance on what constitutes a medical device versus general wellness software, a distinction that carries significant regulatory implications. The American Hospital Association (AHA) submitted formal comments to the FDA in August 2026, urging the agency to clarify its approach to clinical decision support (CDS) software, which uses AI to analyze patient data and generate care recommendations.

The regulatory landscape distinguishes between AI tools that support clinician decision-making and those that attempt to replace clinical judgment. Under Section 3060 of the 21st Century Cures Act, certain low-risk decision support software can be exempted from FDA oversight if it meets specific criteria. The AHA recommended that the FDA make permanent its January 2026 guidance providing enforcement discretion for CDS software that produces only one clinical recommendation, rather than treating this flexibility as temporary.

• Clinical Decision Support Tools: AI systems that analyze large amounts of clinical data to generate patient-specific care recommendations, supporting but not replacing provider judgment
• General Wellness Products: Consumer-facing applications that track health metrics like heart rate or blood pressure, which face different regulatory requirements than medical devices
• Medical Device Software: AI systems intended to diagnose, treat, or prevent disease, which require FDA approval and ongoing oversight

A key tension in the regulatory framework involves wellness products that provide notifications when health metrics fall outside normal ranges. The AHA raised concerns that such notifications could inadvertently expand a product's scope beyond its intended use, creating confusion for both consumers and healthcare providers about whether they are using a medical device or a wellness tool. The organization recommended that the FDA either clarify this guidance or remove it entirely to prevent unintended regulatory consequences.

Why Does the Shift From Experimentation to Implementation Matter?

The transition from experimental AI to deployed systems represents a fundamental maturation of healthcare technology. Early AI research often focuses on achieving high performance on benchmark tests or demonstrating proof-of-concept in controlled settings. Real-world implementation, by contrast, requires that systems work reliably across diverse patient populations, integrate smoothly with existing clinical workflows, maintain data security and privacy, and ultimately improve measurable health outcomes.

This shift has practical implications for how health systems allocate resources and how technology vendors design their products. Rather than pursuing the most technically sophisticated AI models, organizations are increasingly asking which tools will actually reduce clinician burden, improve patient safety, and enhance care quality in their specific settings. The emphasis on trusted data governance and workforce support reflects recognition that AI is only as valuable as the human systems and processes that surround it.

As healthcare continues integrating AI across clinical settings, from radiology and pathology to fertility medicine and general practice, the industry is learning that successful implementation depends less on algorithmic breakthroughs and more on thoughtful governance, clear regulatory frameworks, and genuine partnership between technology developers and clinical teams. The next chapter of healthcare AI will be written not in research papers, but in hospital corridors and clinic examination rooms where patients receive care.